Renal Anemia | Access and Reimbursement | US | 2020
This content examines the market access factors that influence the success or failure of therapies for renal anemia. It is based on primary research with U.S. nephrologists and MCO pharmacy and medical directors. We explore how payers and physicians interact and how reimbursement decisions affect the prescribing and uptake of specific therapies at the brand level.
QUESTIONS ANSWERED
- How do payers reimburse specific therapies for the treatment of renal anemia, and what restrictions do they impose?
- What factors most influence payers’ reimbursement decisions for specific renal anemia therapies?
- What roles do reimbursement, restrictions, and patient costs play in physicians’ choice of therapy for this indication?
- How do payers anticipate reimbursing emerging therapies at various prices?
- What patient share can emerging therapies garner under various reimbursement scenarios?
- How can pharmaceutical companies enable their products to thrive in this market access environment?
Related Market Assessment Reports
Report
Scleroderma (Systemic Sclerosis) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Scleroderma (Systemic Sclerosis) (US)
Scleroderma (systemic sclerosis) (SSc) is a rare progressive autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that can manifest as Raynaud’s phenomenon…
Report
Hypertrophic Cardiomyopathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hypertrophic Cardiomyopathy (US)
HCM is a genetic heart condition characterized by thickened myocardium and left ventricular hypertrophy, often linked to sarcomere mutations. While some patients remain asymptomatic, common…
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Geographic Focus: China – Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – China In-Depth (China)
The NHL therapy market in China is poised for significant growth over the next decade, driven by the introduction of novel therapies and the continued uptake and label expansion of premium-priced…
